Corvus Pharmaceuticals Inc (CRVS)

May 21, 2026

Corvus drops after early-stage trial data for eczema therapy - MSN

May 21, 2026

May 20, 2026

Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang

May 20, 2026

May 20, 2026

Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan

May 20, 2026

May 20, 2026

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com

May 20, 2026

May 20, 2026

Biotech Corvus heads to Jefferies and Goldman Sachs health conferences - Stock Titan

May 20, 2026

May 20, 2026

Why Corvus Pharmaceuticals (CRVS) Is Down 28.0% After Rebound‑Free Soquelitinib Phase 1 Eczema Data And What's Next - Sahm

May 20, 2026

May 19, 2026

Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha

May 19, 2026

May 18, 2026

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst CallSlideshow (NASDAQ:CRVS) 2026-05-18 - Seeking Alpha

May 18, 2026

May 17, 2026

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase - sharewise.com

May 17, 2026

May 17, 2026

Boxer Capital Management's New Stake in Corvus Pharmaceuticals: SEC Filing DetailsNews and Statistics - IndexBox

May 17, 2026

May 17, 2026

Corvus Pharmaceuticals, Inc.Common Stock (NQ: CRVS - FinancialContent

May 17, 2026

May 15, 2026

Point72, Steven A. Cohen show 0% stake in Corvus (CRVS) - Stock Titan

May 15, 2026

May 15, 2026

A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40 - Moomoo

May 15, 2026

May 15, 2026

Sirenia/Alex Silverstein disclose 6.83M warrant shares for Corvus (NASDAQ: CRVS) - Stock Titan

May 15, 2026

May 14, 2026

Corvus Pharmaceuticals : CRVS SID Investor Meeting Presentation FINAL - marketscreener.com

May 14, 2026

May 14, 2026

Corvus Pharmaceuticals Reports Positive Final Phase 1 Results for Soquelitinib in Atopic Dermatitis at SID 2026 Annual Meeting 16 - Minichart

May 14, 2026

May 14, 2026

Corvus drops on trial data for eczema therapy (CRVS:NASDAQ) - Seeking Alpha

May 14, 2026

May 14, 2026

Corvus Pharmaceuticals Down Over 11%, On Track for Largest Percent Decrease Since March 2025 -- Data Talk - Moomoo

May 14, 2026

May 14, 2026

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting - markets.businessinsider.com

May 14, 2026

May 14, 2026

Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results - TipRanks

May 14, 2026

May 14, 2026

Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety - TradingView

May 14, 2026

May 14, 2026

Corvus (Nasdaq: CRVS) details Phase 1 soquelitinib eczema results and next trials - Stock Titan

May 14, 2026

May 14, 2026

Drug-free remissions seen after short atopic dermatitis treatment - Stock Titan

May 14, 2026

May 12, 2026

Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40 - Moomoo

May 12, 2026

May 12, 2026

CRVS PE Ratio & Valuation, Is CRVS Overvalued - Intellectia AI

May 12, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 12, 2026

Number of shareholders of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView

May 12, 2026

May 12, 2026

Number of shareholders of Corvus Pharmaceuticals, Inc. – TRADEGATE:C17 - TradingView

May 12, 2026

May 12, 2026

Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS - Sahm

May 12, 2026

May 11, 2026

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo

May 11, 2026

May 10, 2026

Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS) - Yahoo Finance

May 10, 2026

May 09, 2026

Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33 - Moomoo

May 09, 2026

May 09, 2026

MSN Money - MSN

May 09, 2026

May 08, 2026

Corvus: Q1 Earnings Snapshot - theheraldreview.com

May 08, 2026

May 08, 2026

Corvus Pharmaceuticals earnings up next as AD trial looms By Investing.com - Investing.com Australia

May 08, 2026

May 07, 2026

Corvus Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo

May 07, 2026

May 07, 2026

Corvus (NASDAQ: CRVS) widens loss but lifts cash to $236.7M after equity raise - Stock Titan

May 07, 2026

May 07, 2026

Corvus to show eczema data backing drug-free remission potential - Stock Titan

May 07, 2026

May 07, 2026

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times

May 07, 2026

May 07, 2026

Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 07, 2026

May 07, 2026

Cash runway to 2028 as Corvus (NASDAQ: CRVS) advances soquelitinib - Stock Titan

May 07, 2026

May 07, 2026

Corvus Pharmaceuticals earnings up next as AD trial looms - Investing.com India

May 07, 2026

May 05, 2026

CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan

May 05, 2026

May 03, 2026

A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board - Sahm

May 03, 2026

May 02, 2026

Could Corvus Pharmaceuticals’ (CRVS) New Board Appointment Reframe Its Immunology Strategy And Competitive Edge? - Sahm

May 02, 2026

May 01, 2026

Corvus Pharmaceuticals (CRVS.US) will release its earnings report after the market closes on May 7. - Moomoo

May 01, 2026